Galapagos NV Launches New Subscription Right Plan for Management

Galapagos ( (GLPG) ) has shared an update.

On August 7, 2025, Galapagos NV announced the creation of 1,800,000 subscription rights under a new plan approved by its Board of Directors. This initiative, known as ‘Subscription Right Plan 2025 (B)’, is aimed at compensating senior management and involves an exercise term of eight years with a price of €28.16 per right. The plan is part of Galapagos’ strategy to enhance its market positioning and incentivize its workforce, potentially impacting the company’s share capital and voting rights structure.

The most recent analyst rating on (GLPG) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

The overall stock score reflects significant financial challenges, particularly in cash flow and profitability, overshadowed by strong technical indicators suggesting positive market momentum. While the company has strategic plans to expand its pipeline and manufacturing, high restructuring costs and anticipated cash burn remain key concerns.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company with operations in Europe, the U.S., and Asia, dedicated to transforming patient outcomes through life-changing science and innovation. The company focuses on high unmet medical needs, leveraging science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. Galapagos is committed to challenging the status quo and delivering results for patients, employees, and shareholders.

Average Trading Volume: 364,170

Technical Sentiment Signal: Hold

Current Market Cap: $2.21B

For detailed information about GLPG stock, go to TipRanks’ Stock Analysis page.